Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial

Abaloparatide is a 34 –amino acid peptide that selectively binds to the RG conformation of the parathyroid hormone receptor type 1. It was developed for the treatment of women with postmenopausal osteoporosis at high risk of fracture. In ACTIVE, an 18-month phase 3 study (NCT01343004), abaloparatide increased bone mine ral density (BMD), decreased the risk of vertebral and nonvertebral fractures compared with placebo, and decreased the risk of major osteoporotic fractures compared with placebo and teriparatide.

Source: Bone - October 22, 2018 Category: Orthopaedics Authors: P.D. Miller, G. Hattersley, E. Lau, L.A. Fitzpatrick, A.G. Harris, G.C. Williams, M.-Y. Hu, B.J. Riis, L. Russo, C. Christiansen Tags: Full Length Article Source Type: research